Taken together, the above data suggest that normal cells retain intact convergent pathways to control replication licensing, whereas cancer cells lack these pathways and thus are more sensitive to agents targeting licensing components, as the CDT1/Geminin protein complex (Blow and Gillespie, 2008; Petropoulos et al., 2019). This evidence concerns the gene CDT1 and cancer.